Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22524566 | 0.89 | STS (0.49) | STSMAPTSMN1; SMN2GPR119THRB | |
| SCHEMBL29021455 | 0.87 | STS (0.47) | STSMAPTSMN1; SMN2GPR119THRB | |
| SCHEMBL3319319 | 0.86 | GPR119 (0.47) | STSMAPTSMN1; SMN2GPR119 | |
| SCHEMBL29021454 | 0.86 | STS (0.53) | STSMAPTSMN1; SMN2GPR119THRB | |
| SCHEMBL2364532 | 0.85 | MEN1 (0.43) | — | |
| SCHEMBL1513166 | 0.83 | GPR119 (0.53) | STSMAPTSMN1; SMN2GPR119THRB | |
| SCHEMBL30233524 | 0.83 | GPR119 (0.53) | STSMAPTSMN1; SMN2GPR119THRB | |
| SCHEMBL28059306 | 0.83 | HCRTR2 (0.36) | MAPTSMN1; SMN2GPR119 | |
| SCHEMBL2553555 | 0.81 | GPR119 (0.54) | STSMAPTSMN1; SMN2GPR119THRB | |
| SCHEMBL4675703 | 0.81 | GPR119 (0.51) | STSMAPTSMN1; SMN2GPR119THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12239638-B2 | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4491223-A2 | COMPOUND FOR USE IN THE TREATMENT OF NEUROGENIC ORTHOSTATIC HYPOTENSION | Theravance Biopharma R&D IP, LLC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240316024-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-09-26 | — | — | US | disclosed |
| EP-3784655-B1 | PROCESS FOR PREPARING 2-(1-(TERT-BUTOXYCARBONYL)PIPERIDINE-4-YL)BENZOIC ACID | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11723900-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723900-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723900-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230201181-A1 | CRYSTALLINE FORM OF A 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230201181-A1 | CRYSTALLINE FORM OF A 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230201181-A1 | CRYSTALLINE FORM OF A 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20100125141-A1 | PROCESS FOR PREPARING 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-05-20 | — | — | US | disclosed |
| US-20100125141-A1 | PROCESS FOR PREPARING 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-05-20 | — | — | US | disclosed |
| US-20100125141-A1 | PROCESS FOR PREPARING 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-05-20 | — | — | US | disclosed |
| US-20100125093-A1 | CRYSTALLINE FORM OF A 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-05-20 | — | — | US | disclosed |
| US-20100125093-A1 | CRYSTALLINE FORM OF A 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-05-20 | — | — | US | disclosed |
| US-20100125093-A1 | CRYSTALLINE FORM OF A 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-05-20 | — | — | US | disclosed |
| US-20100125092-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-05-20 | — | — | US | disclosed |
| US-20100125092-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-05-20 | — | — | US | disclosed |
| US-20100125092-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-05-20 | — | — | US | disclosed |
| WO-2010056939-A1 | CRYSTALLINE FORM OF A 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND | THERAVANCE, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12239638-B2 | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound | REN, PKD2, UACA | STS 3401/4885MAPT 131/4885SMN1; SMN2 3197/4885 |
| US-11723900-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | STS 2041/4885MAPT 1250/4885SMN1; SMN2 1338/4885 |
| US-20100125092-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | STS 2041/4885MAPT 1250/4885SMN1; SMN2 1338/4885 |
| US-20240316024-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | STS 2041/4885MAPT 1250/4885SMN1; SMN2 1338/4885 |
| US-20100125141-A1 | PROCESS FOR PREPARING 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | STS 1113/4885MAPT 1337/4885SMN1; SMN2 1362/4885 |
| US-20230201181-A1 | CRYSTALLINE FORM OF A 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND | REN, PKD2, UACA | STS 3401/4885MAPT 131/4885SMN1; SMN2 3197/4885 |
| US-20100125093-A1 | CRYSTALLINE FORM OF A 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND | REN, PKD2, UACA | STS 3401/4885MAPT 131/4885SMN1; SMN2 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.